According to the latest report by IMARC Group, titled “Ventricular Assist Devices Market Report by Product (Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), Biventricular Assist Device (BiVAD), and Others), Flow Type (Pulsatile Flow, Non-Pulsatile or Continuous Flow), Product Type (Implantable Ventricular Assist Devices, Non-implantable Ventricular Assist Devices), Application (Bridge-to-Transplant (BTT) Therapy, Destination Therapy, Bridge to Recovery and Bridge to Candidacy), End User (Ambulatory Surgery Centers, Hospital, and Others), and Region 2025-2033,” the global ventricular assist devices market reached a value of USD 2.1 Billion in 2024. Ventricular assist devices (VADs) are circulatory support equipment that ensures the proper flow of blood in one’s body. They function by pumping blood from the lower chambers of ventricles to the rest of the organs. They are equipped with an electronic controller, tubes and a power source that assist in cardiac circulation among patients with heart failure. As a result, they are considered to be a preferred therapeutic solution for patients suffering from end-stage heart failure as VADs help increase their life expectancy with an improved quality of life
Global Ventricular Assist Devices Market Trends:
The global market is primarily driven by the increasing prevalence of cardiovascular diseases among the masses. In line with this, the changing lifestyle patterns of individuals and the busy schedules led by working professionals are providing an impetus to the market growth. Moreover, the rising geriatric population, which is more susceptible to developing medical ailments, is providing an impetus to the market growth. Furthermore, various technological advancements across the healthcare sector, along with the miniaturization of VADs, are significantly contributing to the market growth across the globe. Additionally, increasing funding and investments by public and private firms to upgrade the existing healthcare infrastructure are positively influencing the market growth. Other factors, including rising healthcare expenditure, continuous product innovations and extensive research and development (R&D) activities conducted by key players, are further projected to drive the market growth. On account of the aforementioned factors, the market is anticipated to reach a value of USD 4.3 Billion by 2033, growing at a CAGR of 8.06% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Flow Type, Product Type, Application, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Abiomed Inc., Berlin Heart GmbH (Syscore GmbH), Bivacor Inc., Calon Cardio, Cardiacassist Inc. (LivaNova PLC), CHF Solutions Inc., Jarvik Heart Inc., MAQUET GmbH (Getinge), Medtronic Inc., Syncardia Systems LLC (Versa Capital Management LLC), TandemLife (LivaNova PLC) and Terumo Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
Tel no: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com